KR20150132449A - 재조합 인자 viii 제제 - Google Patents

재조합 인자 viii 제제 Download PDF

Info

Publication number
KR20150132449A
KR20150132449A KR1020157029441A KR20157029441A KR20150132449A KR 20150132449 A KR20150132449 A KR 20150132449A KR 1020157029441 A KR1020157029441 A KR 1020157029441A KR 20157029441 A KR20157029441 A KR 20157029441A KR 20150132449 A KR20150132449 A KR 20150132449A
Authority
KR
South Korea
Prior art keywords
ser
leu
thr
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157029441A
Other languages
English (en)
Korean (ko)
Inventor
더 치엔 왕
싱항 마
넬리 츠베트코바
Original Assignee
바이엘 헬스케어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 헬스케어 엘엘씨 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20150132449A publication Critical patent/KR20150132449A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A61K47/48—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157029441A 2013-03-15 2014-03-11 재조합 인자 viii 제제 Withdrawn KR20150132449A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US61/799,495 2013-03-15
US201361869191P 2013-08-23 2013-08-23
US61/869,191 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (1)

Publication Number Publication Date
KR20150132449A true KR20150132449A (ko) 2015-11-25

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029441A Withdrawn KR20150132449A (ko) 2013-03-15 2014-03-11 재조합 인자 viii 제제

Country Status (17)

Country Link
US (1) US20160030524A1 (enExample)
EP (1) EP2970430A4 (enExample)
JP (1) JP2016518321A (enExample)
KR (1) KR20150132449A (enExample)
CN (1) CN105209487A (enExample)
AU (1) AU2014237111B2 (enExample)
BR (1) BR112015022730A2 (enExample)
CA (1) CA2905739A1 (enExample)
HK (1) HK1213273A1 (enExample)
MX (1) MX2015012905A (enExample)
PE (1) PE20160121A1 (enExample)
RU (1) RU2015144076A (enExample)
SG (2) SG10201803999UA (enExample)
TW (1) TW201521761A (enExample)
UY (1) UY35412A (enExample)
WO (1) WO2014150477A1 (enExample)
ZA (1) ZA201507684B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
CN116949052A (zh) 2015-11-13 2023-10-27 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
ES2435141T3 (es) * 1999-02-22 2013-12-18 University Of Connecticut Nuevas formulaciones de factor VIII libres de albúmina
EP2110385A1 (en) * 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
SI1824988T1 (sl) * 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Also Published As

Publication number Publication date
WO2014150477A1 (en) 2014-09-25
RU2015144076A (ru) 2017-04-24
ZA201507684B (en) 2017-06-28
MX2015012905A (es) 2016-06-16
UY35412A (es) 2014-10-31
SG10201803999UA (en) 2018-06-28
JP2016518321A (ja) 2016-06-23
AU2014237111B2 (en) 2018-06-21
CA2905739A1 (en) 2014-09-25
AU2014237111A1 (en) 2015-10-08
EP2970430A4 (en) 2017-01-11
SG11201507618YA (en) 2015-10-29
PE20160121A1 (es) 2016-03-03
BR112015022730A2 (pt) 2017-10-31
US20160030524A1 (en) 2016-02-04
EP2970430A1 (en) 2016-01-20
HK1213273A1 (zh) 2016-06-30
CN105209487A (zh) 2015-12-30
TW201521761A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
EP2772500B1 (en) Site-directed modification of FVIII
JP2015527350A (ja) 第ｖｉｉｉ因子の液体製剤
JP2008525491A (ja) ポリマー−フォンビルブラント因子結合体
KR102192494B1 (ko) 인자 viii 제형
KR20150132449A (ko) 재조합 인자 viii 제제
JP7626369B2 (ja) ヘモペキシン製剤
US20140274902A1 (en) Recombinant fviii formulations
AU2012203813B2 (en) Site-directed modification of FVIII
AU2013203348B2 (en) Site-directed modification of FVIII
AU2020256332A1 (en) Site-directed modification of FVIII
CN112138149A (zh) 重组凝血因子viii制剂
HK1243093A1 (en) Site-directed modification of fviii
HK1236109B (en) Factor viii formulation
HK1236109A1 (en) Factor viii formulation
HK1226754A1 (en) Site-directed modification of fviii
HK1117875B (en) Site-directed modification of fviii
HK1182121B (en) Site-directed modification of fviii

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid